Parsippany, New Jersey, USA, November 6, 2026
Onkos Surgical, Inc., a medical technology company specializing in advanced solutions for complex orthopedic conditions, has announced that the U.S. Food and Drug Administration (FDA) has granted a new 510(k) clearance for its NanoCept® Antibacterial Technology. The latest regulatory clearance expands the application of NanoCept across a broader range of titanium components used in the company’s ELEOS™ Limb Salvage System. The newly cleared components include proximal femurs, tibial baseplates and augments, and cemented bowed segmental stems. The development represents another important milestone in Onkos Surgical’s efforts to expand antibacterial implant technology for patients undergoing complex orthopedic reconstruction procedures. This is the fourth FDA 510(k) clearance for NanoCept since the technology received its original De Novo marketing authorization in April 2024. The expanded clearance strengthens the company’s portfolio of antibacterial-coated orthopedic implants and supports its strategy of addressing bacterial contamination challenges during complex surgical procedures, particularly in patients requiring tumor reconstruction, revision surgery and limb salvage treatments.
FDA Clearance Expands NanoCept Technology Across Titanium Implants
The latest FDA 510(k) clearance allows Onkos Surgical to extend NanoCept antibacterial coating technology to additional titanium components within its ELEOS Limb Salvage System. These components include proximal femoral implants, tibial baseplates, tibial augments and cemented bowed segmental stems. The expanded application also permits broader NanoCept coverage on previously cleared titanium components. The regulatory milestone increases the availability of antibacterial-coated implant options for surgeons performing complex orthopedic procedures. Patients undergoing limb salvage and revision joint replacement surgeries can face increased risks of bacterial contamination due to multiple previous procedures, extensive tissue reconstruction and the complexity of implanted orthopedic devices. Periprosthetic joint infection (PJI) is a particularly serious complication because bacteria can attach to implant surfaces and form biofilms, making infections difficult to manage. NanoCept is designed to address one part of this challenge by reducing bacterial contamination on implant surfaces before implantation. The technology provides an additional implant-surface protection approach for orthopedic surgeons treating patients with complex reconstructive requirements.
NanoCept Demonstrates Up to 99.999% Bacterial Reduction
NanoCept is a proprietary antibacterial implant coating developed to reduce bacterial contamination resulting from the deposition of microorganisms on device surfaces in the operating room before implantation. According to Onkos Surgical, extensive preclinical testing demonstrated up to a 99.999% reduction in bacteria commonly encountered in operating room environments. The testing included clinically relevant bacterial organisms associated with surgical contamination and orthopedic implant infections. The technology is intended to provide an antibacterial surface on implant components during the period before surgical implantation. This is particularly relevant in complex reconstruction procedures, where large implants and extensive surgical exposure can create additional opportunities for bacterial contamination. However, an important distinction is that NanoCept is not intended to treat existing infections. Its clinical impact in preventing infections or reducing infection risk in patients has not yet been evaluated in human clinical trials. Therefore, the reported bacterial reduction findings should be understood as preclinical evidence rather than demonstrated clinical infection-prevention outcomes. The technology is designed to complement established infection-control practices and does not replace standard surgical infection-prevention protocols.
Advertisement
Manufacturing Expansion Supports Future Commercial Growth
Alongside regulatory expansion, Onkos Surgical continues to invest in its manufacturing and innovation capabilities to support the wider availability of NanoCept-coated orthopedic implants. The company has strengthened its internal manufacturing infrastructure through the establishment of the NanoCept Innovation Center in Bridgewater, New Jersey. These investments are intended to support production capacity, manufacturing innovation and the continued development of antibacterial-coated implant components. The company’s ELEOS Limb Salvage System is designed for patients requiring complex orthopedic reconstruction, including individuals undergoing surgery for bone tumors, severe trauma and revision procedures. Onkos Surgical works with leading academic medical institutions and orthopedic specialists to develop solutions that combine implant design, patient-specific surgical planning, three-dimensional anatomical modeling and advanced manufacturing. According to company Founder and Chief Executive Officer Patrick Treacy, the latest FDA clearance reinforces the company’s commitment to expanding antibacterial implant options while continuing to invest in regulatory development and manufacturing innovation. Orthopedic surgeon Dr. Johannes Plate of the University of Pittsburgh Medical Center also highlighted the importance of broader antibacterial implant availability for patients undergoing complex joint replacement and limb salvage procedures.
Overall, Onkos Surgical’s latest FDA 510(k) clearance represents an important advancement in antibacterial technology for orthopedic implants. By expanding NanoCept across additional titanium components, the company is increasing the availability of its technology within the ELEOS Limb Salvage System. Continued regulatory development, manufacturing investments and further clinical evaluation will be important in determining the technology’s broader role in orthopedic reconstruction and infection-control strategies.
Source: Onkos Surgical press release
